Mendelian randomization indicates that TNF is not causally associated with Alzheimer's disease

Shea J. Andrews; Alison Goate

doi:10.1016/j.neurobiolaging.2019.09.003

Mendelian randomization indicates that TNF is not causally associated with Alzheimer's disease

Shea J. Andrews, Alison Goate

Research output: Contribution to journal › Article › peer-review

3 Scopus citations

Abstract

Epidemiological research has suggested that inhibition of tumor necrosis factor (TNF)-α in patients with rheumatoid arthritis (RA) reduces the overall risk of Alzheimer's disease (AD). TNF-α antagonists have been suggested as a potential treatment for AD. We used a two-sample Mendelian randomization design to examine the causal relationship between blood TNF expression, serum TNF-α levels, and RA on AD risk. Our results do not support a causal relationship between TNF expression, serum TNF-α levels, and RA on AD risk.

Original language	English
Pages (from-to)	241.e1-241.e3
Journal	Neurobiology of Aging
Volume	84
DOIs	https://doi.org/10.1016/j.neurobiolaging.2019.09.003
State	Published - Dec 2019

Keywords

Alzheimer's disease
Mendelian randomization
Rheumatoid arthritis
TNF
Tumor necrosis factor

Access to Document

10.1016/j.neurobiolaging.2019.09.003

Cite this

@article{f43f5d4f5ea744b187da6586d13eb108,

title = "Mendelian randomization indicates that TNF is not causally associated with Alzheimer's disease",

abstract = "Epidemiological research has suggested that inhibition of tumor necrosis factor (TNF)-α in patients with rheumatoid arthritis (RA) reduces the overall risk of Alzheimer's disease (AD). TNF-α antagonists have been suggested as a potential treatment for AD. We used a two-sample Mendelian randomization design to examine the causal relationship between blood TNF expression, serum TNF-α levels, and RA on AD risk. Our results do not support a causal relationship between TNF expression, serum TNF-α levels, and RA on AD risk.",

keywords = "Alzheimer's disease, Mendelian randomization, Rheumatoid arthritis, TNF, Tumor necrosis factor",

author = "Andrews, {Shea J.} and Alison Goate",

note = "Funding Information: SJA and AMG were supported by the JPB Foundation ( http://www.jpbfoundation.org ). SJA has no conflicts of interest to declare. AMG served on the scientific advisory board for Denali Therapeutics from 2015-2018. She has also served as a consultant for Biogen, Cognition Therapeutics, AbbVie, Pfizer, GSK, Eisai and Illumina. Publisher Copyright: {\textcopyright} 2019 Elsevier Inc.",

year = "2019",

month = dec,

doi = "10.1016/j.neurobiolaging.2019.09.003",

language = "English",

volume = "84",

pages = "241.e1--241.e3",

journal = "Neurobiology of Aging",

issn = "0197-4580",

publisher = "Elsevier Inc.",

}

TY - JOUR

T1 - Mendelian randomization indicates that TNF is not causally associated with Alzheimer's disease

AU - Andrews, Shea J.

AU - Goate, Alison

N1 - Funding Information: SJA and AMG were supported by the JPB Foundation ( http://www.jpbfoundation.org ). SJA has no conflicts of interest to declare. AMG served on the scientific advisory board for Denali Therapeutics from 2015-2018. She has also served as a consultant for Biogen, Cognition Therapeutics, AbbVie, Pfizer, GSK, Eisai and Illumina. Publisher Copyright: © 2019 Elsevier Inc.

PY - 2019/12

Y1 - 2019/12

N2 - Epidemiological research has suggested that inhibition of tumor necrosis factor (TNF)-α in patients with rheumatoid arthritis (RA) reduces the overall risk of Alzheimer's disease (AD). TNF-α antagonists have been suggested as a potential treatment for AD. We used a two-sample Mendelian randomization design to examine the causal relationship between blood TNF expression, serum TNF-α levels, and RA on AD risk. Our results do not support a causal relationship between TNF expression, serum TNF-α levels, and RA on AD risk.

AB - Epidemiological research has suggested that inhibition of tumor necrosis factor (TNF)-α in patients with rheumatoid arthritis (RA) reduces the overall risk of Alzheimer's disease (AD). TNF-α antagonists have been suggested as a potential treatment for AD. We used a two-sample Mendelian randomization design to examine the causal relationship between blood TNF expression, serum TNF-α levels, and RA on AD risk. Our results do not support a causal relationship between TNF expression, serum TNF-α levels, and RA on AD risk.

KW - Alzheimer's disease

KW - Mendelian randomization

KW - Rheumatoid arthritis

KW - TNF

KW - Tumor necrosis factor

UR - http://www.scopus.com/inward/record.url?scp=85072779660&partnerID=8YFLogxK

U2 - 10.1016/j.neurobiolaging.2019.09.003

DO - 10.1016/j.neurobiolaging.2019.09.003

M3 - Article

C2 - 31587925

AN - SCOPUS:85072779660

SN - 0197-4580

VL - 84

SP - 241.e1-241.e3

JO - Neurobiology of Aging

JF - Neurobiology of Aging

ER -

Mendelian randomization indicates that TNF is not causally associated with Alzheimer's disease

Abstract

Keywords

Access to Document

Fingerprint

Cite this